The news at a glance

Cholesterol drugs: Doubts about two favorites; E-commerce: IAC breakup gets the go-ahead; Broadcasting: Cloudy skies for Clear Channel; Manufacturing: Japan’s factories cut back; Banking: Citi’s reshuffling begins

Cholesterol drugs: Doubts about two favorites

Vytorin and Zetia, two widely prescribed anti-­cholesterol treatments, “may not work and should be used only as a last resort,” said Alex Berenson in The New York Times. A panel of four leading cardiologists announced that startling conclusion this week after studying the results of a two-year clinical trial, which showed that Vytorin, a combination of Zetia and another drug, “did not slow, and might speed up, the growth of fatty plaques in arteries.” U.S. physicians write more than 3 million prescriptions for Vytorin and Zetia each month, believing that they’re more effective at reducing heart disease than an older class of drugs known as statins.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us